Literature DB >> 14725849

Mood effects of antiepileptic drugs.

Rianne Reijs1, Albert P Aldenkamp, Marc De Krom.   

Abstract

This article reviews our knowledge about a specific subgroup of chronic CNS-related side effects of antiepileptic drugs (AED) treatment, i.e., the effects of AEDs on mood. In line with a recent hypothesis, using the experience of AED treatment in psychiatry, we examined whether mood effects are related to the known anticonvulsant mechanisms of action of the AEDs. Specifically we examined whether AEDs, acting through potentiation of GABAergic neurotransmitter release, have "sedating" effects on mood, whereas AEDs that act through the reduction of excitatory glutamate neurotransmitter release have "activating" effects on mood. The results of this review yield evidence that there are relationships between the known anticonvulsant mechanisms of action of the AEDs and mood effects. Mood effects occur especially when the drugs have a sustained effect on neuronal mechanisms, in particular when the inhibitory or excitatory neurotransmitter release is altered. Drugs with "use-dependent" impact on sodium or calcium channels probably have a more transient impact and do not lead to interictal stable mood effects. Drugs with multiple mechanisms of action seem to combine a favorable efficacy profile with an increased risk of severe mood problems. The quality of the evidence, however, is not conclusive and there are many paradoxical results. One reason for this lack of "fit" may be the use in this review of a simplified classification, based only on the predominant mechanism of action to classify a drug. Only a limited number of AEDs (ethosuximide, tiagabine) are characterized by a single anticonvulsant mechanism of action. Probably more detailed coupling of mechanisms of action (e.g., inspecting the type and route of impact on GABA release) and mood effects may give less confusing results. The use of magnetic resonance imaging techniques such as spectroscopy may provide interesting results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14725849     DOI: 10.1016/j.yebeh.2003.11.009

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  7 in total

Review 1.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 2.  Suicidality and antiepileptic drugs: is there a link?

Authors:  Vladimir V Kalinin
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

4.  Acute topiramate differentially affects human aggressive responding at low vs. moderate doses in subjects with histories of substance abuse and antisocial behavior.

Authors:  Scott D Lane; Joshua L Gowin; Charles E Green; Joel L Steinberg; F Gerard Moeller; Don R Cherek
Journal:  Pharmacol Biochem Behav       Date:  2009-04       Impact factor: 3.533

5.  Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints.

Authors:  Pim B van der Meer; Johan A F Koekkoek; Martin J van den Bent; Linda Dirven; Martin J B Taphoorn
Journal:  J Neurooncol       Date:  2021-04-06       Impact factor: 4.130

6.  Tantrums, Emotion Reactions and Their EEG Correlates in Childhood Benign Rolandic Epilepsy vs. Complex Partial Seizures: Exploratory Observations.

Authors:  Michael Potegal; Elena H Drewel; John T MacDonald
Journal:  Front Behav Neurosci       Date:  2018-03-09       Impact factor: 3.558

7.  Epilepsy and suicide: pathogenesis, risk factors, and prevention.

Authors:  Alberto Verrotti; Alessandra Cicconetti; Barbara Scorrano; Domenico De Berardis; Carla Cotellessa; Francesco Chiarelli; Filippo Maria Ferro
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.